Trial Profile
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-355; MK-3475-355/KEYNOTE-355
- Sponsors Merck Sharp & Dohme Corp.
- 11 Feb 2024 This trial has been Completed in Ireland, According to European Clinical Trials Database record.
- 07 Feb 2024 This trial has been Completed in German, According to European Clinical Trials Database record.
- 03 Feb 2024 This trial has been Completed in Czechia , According to European Clinical Trials Database record.